Role of uric acid in clinical manifestations of ankylosing spondylitis
- Authors: Bazina I.B.1, Krechikova D.G.2, Kozyrev О.А.1, Pavlova М.V.1, Rostkova D.G.1, Konevskikh М.А.1, Mukhina А.А.1
-
Affiliations:
- Smolensk State Medical University, Ministry of Health of Russia
- Clinical hospital «RZhD-Medicine»
- Issue: Vol 35, No 3 (2024)
- Pages: 32-34
- Section: From Practice
- URL: https://journals.eco-vector.com/0236-3054/article/view/629987
- DOI: https://doi.org/10.29296/25877305-2024-03-07
- ID: 629987
Cite item
Open Access
Access granted
Abstract
Prevalence of ankylosing spondylitis (AS) is about 0.2–0.8% and increasing during last decades in Russia. Coronary Heart Disease (CHD) plays an important role in mortality in patients with rheumatic diseases. AS mainly affects able-bodied age persons thus having a significant social and economic impact. There plenty of biomarkers of AS, including those for early diagnosis.
Purpose. To study the level of uric acid (UA) in patients with AS and its role in development of AS.
Materials and methods. A total of 72 medical charts of patients hospitalized at Smolensk Regional Rheumatological Center were evaluated, among them 73.6% were men and 26.4% – women. AS was diagnosed according to classification criteria. Lab tests were done in a central lab using standard methodology. All data collected for each patient was entered into an Excel spreadsheet and analyzed.
Results. Average patients age was 49.6±12.4 years. BMI was 28.1±5.4 kg/m2. Arterial Hypertension (AH) and CHD was diagnosed in 44.4% of patients. Glomerular Filtration Rate (GFR) was 95.1±21.9 mL/min. UA concentration were equal to 301.3±94.3 mmol/L, total cholesterol (TC) – 5.0±1.0 mmol/L, CRP – 60.5±35.1 IU/L. A direct correlation between CRP and BMI was revealed (p<0.005). UA concentration in patients with AS and CHD was 347.3±73.9 mmol/L, while in patients with AS without CHD it was significantly lower: 261.8±77.4 mmol/L (p<0,001). UA concentration in patients with AS and HLA-B27(+) was 345.1±90.8 mmol/L, in patients with AS and HLA-B27(-) – 259.1±75.1 mmol/L (p<0,001). BASDAI in patients with AS was equal to 5.7±2.1. UA concentration in patients with mild to moderate AS was 255.4±77.7 mmol/L; severe AS – 343.4±75.3 mmol/L (p<0.001). Correlations between TC level and BASDAI (p<0.05) as well as between UA level and BASDAI (p<0.05) were revealed.
Conclusion. In patients with AS increased level of UA supports inflammation activity, forces subjective symptoms of the disease (pain), correlates with disease activity and BASDAI. Hyperuricemia increases risk of CHD, worsens prognosis of AS. UA may be considered as a biomarker of disease activity and prognosis of AS, atherosclerosis and cardiovascular diseases.
Keywords
Full Text
About the authors
I. B. Bazina
Smolensk State Medical University, Ministry of Health of Russia
Author for correspondence.
Email: billy-boss@mail.ru
Сandidate of Medical Sciences
Russian Federation, SmolenskD. G. Krechikova
Clinical hospital «RZhD-Medicine»
Email: billy-boss@mail.ru
Сandidate of Medical Sciences
Russian Federation, SmolenskО. А. Kozyrev
Smolensk State Medical University, Ministry of Health of Russia
Email: billy-boss@mail.ru
Professor, MD
Russian Federation, SmolenskМ. V. Pavlova
Smolensk State Medical University, Ministry of Health of Russia
Email: billy-boss@mail.ru
Russian Federation, Smolensk
D. G. Rostkova
Smolensk State Medical University, Ministry of Health of Russia
Email: billy-boss@mail.ru
Russian Federation, Smolensk
М. А. Konevskikh
Smolensk State Medical University, Ministry of Health of Russia
Email: billy-boss@mail.ru
Russian Federation, Smolensk
А. А. Mukhina
Smolensk State Medical University, Ministry of Health of Russia
Email: billy-boss@mail.ru
Russian Federation, Smolensk
References
- Эрдес Ш.Ф., Денисов Л.Н., Маслянский А.Л. и др. Моноклональные антитела к интерлейкину 17 для лечения анкилозирующего спондилита: результаты анализа российской группы больных из рандомизированных двойных слепых плацебоконтролируемых исследований MEASURE 1 и MEASURE 2. Научно-практическая ревматология. 2017; 55 (1): 17–25 [Erdes Sh.F., Denisov L.N., Maslyansky A.L. et al. Anti-interleukin-17 monoclonal antibody for the treatment of ankylosing spondylitis: Results of analysis of a Russian patient group from the randomized, double-blind, placebo-controlled MEASURE 1 and MEASURE 2 trials. Rheumatology Science and Practice. 2017; 55 (1): 17–25 (in Russ.)]. doi: 10.14412/1995-4484-2017-17-25
- Колпаков К.И., Летягина Е.А., Омельченко В.О. и др. Значение трабекулярного костного индекса у молодых мужчин с анкилозирующим спондилитом. Научно-практическая ревматология. 2022; 60 (4): 460–4 [Kolpakov K.I., Letyagina E.A., Omelchenko V.O. et al. Trabecular bone score value in young men with ankylosing spondylitis. Rheumatology Science and Practice. 2022; 60 (4): 460–4 (in Russ.)]. doi: 10.47360/1995-4484-2022-460-464
- Галушко Е.А., Насонов Е.Л. Распространенность ревматических заболеваний в России. Альманах клинической медицины. 2018; 46 (1): 32–9 [Galushko E.A., Nasonov E.L. Prevalence of rheumatic diseases in Russia. Almanac of Clinical Medicine. 2018; 46 (1): 32–9 (in Russ.)]. doi: 10.18786/2072-0505-2018-46-1-32-39
- Bardin T., Richette P. Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol. 2014; 26 (2): 186–91. doi: 10.1097/BOR.0000000000000028
- Meune C., Touze E., Trinqurte L. et al. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analisis of cohort studies. Rheumatology. 2009; 48: 35–40. doi: 10.1093/rheumatology/kep252
- Елисеев М.С., Елисеева М.Е. Современные аспекты патогенеза и коррекции гиперурикемии, а также ассоциированных с ней состояний. Эффективная фармакотерапия. 2019; 15 (8): 32–40 [Eliseev M.S., Eliseeva M.E. Modern Aspects of Pathogenesis and Correction of Hyperuricemia and Associated Conditions. Effective pharmacotherapy. 2019; 15 (8): 32–40 (in Russ.)]. doi: 10.33978/2307-3586-2019-15-8-32-40
- Prajzlerova K., Grobelna K., Pavelka K. et al. An update on biomarkers in axial spondyloarthritis. Autoimmun Rev. 2016; 15 (6): 501–9. doi: 10.1016/j.autrev.2016.02.002
- Александрова Е.Н., Новиков А.А. Лабораторные биомаркеры анкилозирующего спондилита. Научно-практическая ревматология. 2017; 55 (1): 96–103 [Aleksandrova E.N., Novikov A.A. Laboratory biomarkers for ankylosing spondylitis. Rheumatology Science and Practice. 2017; 55 (1): 96–103 (in Russ.)]. doi: 10.14412/1995-4484-2017-96-103
- Reveille J.D. Biomarkers for diagnosis, monitoring of progression, and treatment responses in ankylosing spondylitis and axial spondyloarthritis. Clin Rheumatol. 2015; 34 (6): 1009–18. doi: 10.1007/s10067-015-2949-3
- Дубинина Т.В., Гайдукова И.З. Годзенко А.А. и др. Рекомендации по оценке активности болезни и функционального состояния больных анкилозирующим спондилитом в клинической практике. Научно-практическая ревматология. 2017; 55 (4): 344–50 [Dubinina T.V., Gaidukova I.Z., Godzenko A.A. et al. Guidelines for the assessment of disease activity and functional status in patients with ankylosing spondylitis in clinical practice. Rheumatology Science and Practice. 2017; 55 (4): 344–50 (in Russ.)]. doi: 10.14412/1995-4484-2017-344-350
- Воронина Н.В., Гольмутдинов Д.Д., Маркина О.И. Влияние нестероидных противовоспалительных препаратов – ингибиторов и не ингибиторов ЦОГ – на состояние почек у больных оксалатной нефропатией, коморбидных по остеоартрозу. Дальневосточный медицинский журнал. 2016; 1: 14–9 [Voronina N.V., Gelmutdinov D.D., Markina O.I. Influence of non-steroid anti-inflammatory drugs - COX inhibitors and non-cox inhibitors - on the condition of kidneys of patients suffering from oxalate nephropathy associated with osteoarthrosis. Far East Medical Journal. 2016; 1: 14–9 (in Russ.)].
- Mok Y., Lee S.J., Kim M.S. et al. Serum uric acid and chronic kidney disease: the Severance cohort study. Nephrol Dial Transplant. 2012; 27 (5): 1831–5. doi: 10.1093/ndt/gfr530
- Федеральные клинические рекомендации по диагностике и лечению анкилозирующего спондилита (Болезнь Бехтерева). М., 2013; с. 14 [Federal clinical recommendations on the diagnosis and treatment of ankylosing spondylitis (Bechterew's disease). Moscow, 2013; p. 14 (in Russ.)].
- Kuwabara M., Niwa K., Nishi Y. et al. Relationship between serum uric acid levels and hypertension among Japanese individuals not treated for hyperuricemia and hypertension. Hypertens Res. 2014; 37 (8): 785–9. doi: 10.1038/hr.2014.75
- Atar A.I., Yilmaz O.C., Akin K. et al. Serum uric acid level is an independent risk factor for presence of calcium in coronary arteries: an observational case-controlled study. Anadolu Kardiyol Derg. 2013; 13 (2): 139–45. doi: 10.5152/akd.2013.039
Supplementary files
